Hinova Pharmaceuticals Inc. A Cash Flow-to-Debt Ratio
Hinova Pharmaceuticals Inc. A cash flow-to-debt ratio. Hinova Pharmaceuticals Inc. A (688302) has a Cash Flow-to-Debt Ratio of -1.10x as of December 2024, meaning its operating cash flow of CN¥-187.08 Million could theoretically repay -1% of its total liabilities (CN¥169.33 Million) in one year. See how financially flexible is Hinova Pharmaceuticals Inc. A to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hinova Pharmaceuticals Inc. A (2019–2024)
Cash flow-to-debt ratio of Hinova Pharmaceuticals Inc. A from 2019 to 2024. Historical debt coverage capacity for Hinova Pharmaceuticals Inc. A across 6 annual periods. Also explore net asset growth rate of Hinova Pharmaceuticals Inc. A to track the company's year-over-year net asset growth rate.
Hinova Pharmaceuticals Inc. A Cash Flow-to-Debt Ratio by Year (2019–2024)
Hinova Pharmaceuticals Inc. A cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Hinova Pharmaceuticals Inc. A. For the full cash flow conversion analysis, see Hinova Pharmaceuticals Inc. A cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.10x | CN¥-187.08 Million | CN¥169.33 Million | ▲ +46.2% |
| 2023 | -2.05x | CN¥-255.51 Million | CN¥124.47 Million | ▲ +2.4% |
| 2022 | -2.10x | CN¥-314.92 Million | CN¥149.68 Million | ▼ -78.8% |
| 2021 | -1.18x | CN¥-227.82 Million | CN¥193.59 Million | ▲ +2.3% |
| 2020 | -1.20x | CN¥-243.66 Million | CN¥202.33 Million | ▼ -19.0% |
| 2019 | -1.01x | CN¥-81.43 Million | CN¥80.50 Million | — |